Literature DB >> 21626897

Practical use of the Framingham risk score in primary prevention: Canadian perspective.

N John Bosomworth1.   

Abstract

OBJECTIVE: To review the 2009 Canadian Cardiovascular Society guidelines and provide practical recommendations for physicians. SOURCES OF INFORMATION: Initial review of the references provided with the guidelines led to a search of the PubMed, ACP Journal Club, and Cochrane databases using the key words primary prevention and statin for English language clinical trials, randomized controlled trials, meta-analyses, and reviews conducted with human participants. References from appropriate retrieved articles were also reviewed. MAIN MESSAGE: The guidelines outline low-density lipoprotein cholesterol (LDL-C) thresholds and targets to inform optimal use of statins in the primary prevention of cardiovascular disease (CVD). Family history of CVD and levels of high-sensitivity C-reactive protein (hsCRP) are risk modifiers in calculating the risk score with the new recommendations. An electronic calculator has been developed to facilitate increased uptake of these guidelines. Large numbers of asymptomatic people, particularly the elderly, will become eligible for statin therapy according to these new guidelines. Poor uptake by physicians and patients might result from the need for repeated testing of hsCRP and LDL-C levels in people who do not perceive themselves to be ill. Controversy persists concerning the role of hsCRP in the reclassification of CVD risk, and the concept of treating LDL-C to target has never been tested as an independent variable in a randomized trial. As two-thirds of the LDL-C lowering achieved by a statin occurs at the initial dose, it might be possible to achieve considerable CVD risk reduction for those at risk by treating initially with a mid-dose statin without LDL-C follow-up.
CONCLUSION: A simplified approach might appeal to patients or physicians who find current guidelines too complex, cumbersome, or costly. Success in getting high-risk patients to take statins is key to achieving improved CVD mortality reduction.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21626897      PMCID: PMC3076470     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  41 in total

1.  Sick individuals and sick populations.

Authors:  G Rose
Journal:  Int J Epidemiol       Date:  2001-06       Impact factor: 7.196

Review 2.  Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Authors:  Rodney A Hayward; Timothy P Hofer; Sandeep Vijan
Journal:  Ann Intern Med       Date:  2006-10-03       Impact factor: 25.391

3.  Rosuvastatin in patients with elevated C-reactive protein.

Authors:  Paul S Chan; Brahmajee K Nallamothu; Rodney A Hayward
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

Review 4.  Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues.

Authors:  Yola Moride; Robert A Hegele; Anatoly Langer; Ruth McPherson; David B Miller; Stéphane Rinfret
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

5.  Optimizing statin treatment for primary prevention of coronary artery disease.

Authors:  Rodney A Hayward; Harlan M Krumholz; Donna M Zulman; Justin W Timbie; Sandeep Vijan
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

Review 6.  The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

Authors:  J J Brugts; T Yetgin; S E Hoeks; A M Gotto; J Shepherd; R G J Westendorp; A J M de Craen; R H Knopp; H Nakamura; P Ridker; R van Domburg; J W Deckers
Journal:  BMJ       Date:  2009-06-30

7.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

Review 8.  C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force.

Authors:  David I Buckley; Rongwei Fu; Michele Freeman; Kevin Rogers; Mark Helfand
Journal:  Ann Intern Med       Date:  2009-10-06       Impact factor: 25.391

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis.

Authors:  Colin R Dormuth; Sebastian Schneeweiss; Alan M Brookhart; Greg Carney; Ken Bassett; Stephen Adams; James M Wright
Journal:  Open Med       Date:  2008-08-12
View more
  21 in total

1.  Implications of a newer Framingham model.

Authors:  Cait O'Sullivan
Journal:  Can Fam Physician       Date:  2012-04       Impact factor: 3.275

2.  Change in predicted 10-year and lifetime cardiovascular disease risk after Roux-en-Y gastric bypass.

Authors:  Amanda S Hinerman; Emma J M Barinas-Mitchell; Samar R El Khoudary; Anita P Courcoulas; Abdus S Wahed; Wendy C King
Journal:  Surg Obes Relat Dis       Date:  2020-04-19       Impact factor: 4.734

3.  Puzzling result.

Authors:  Christian Dufour
Journal:  Can Fam Physician       Date:  2011-07       Impact factor: 3.275

4.  Reliable tool.

Authors:  Marina Sapozhnikov
Journal:  Can Fam Physician       Date:  2011-07       Impact factor: 3.275

5.  Association between dehydroepiandrosterone levels and cardiovascular risk in public sector health workers in a Peruvian region.

Authors:  Ricardo J Rojas; Janett V Chávez-Sosa; Rosmery Gutierrez-Ajalcriña; Salomón Huancahuire-Vega
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-06-19

6.  Prediction of first cardiovascular disease event in 2.9 million individuals using Danish administrative healthcare data: a nationwide, registry-based derivation and validation study.

Authors:  Daniel Mølager Christensen; Matthew Phelps; Thomas Gerds; Morten Malmborg; Anne-Marie Schjerning; Jarl Emanuel Strange; Mohamad El-Chouli; Lars Bruun Larsen; Emil Fosbøl; Lars Køber; Christian Torp-Pedersen; Suneela Mehta; Rod Jackson; Gunnar Gislason
Journal:  Eur Heart J Open       Date:  2021-08-02

7.  The ten-year risk of developing cardiovascular disease among public health workers in North-Central Nigeria using Framingham and atherogenic index of plasma risk scores.

Authors:  Olubunmi Abiola Olubiyi; Bosede Folashade Rotimi; Munirat Ayoola Afolayan; Bilqis Wuraola Alatishe-Muhammad; Olufemi Mubo Olubiyi; Ahmed Dahiru Balami
Journal:  BMC Public Health       Date:  2022-04-27       Impact factor: 4.135

8.  Five-year incidence of chronic kidney disease (stage 3-5) and associated risk factors in a Spanish cohort: the MADIABETES Study.

Authors:  Miguel A Salinero-Fort; Francisco J San Andrés-Rebollo; Carmen de Burgos-Lunar; Paloma Gómez-Campelo; Rosa M Chico-Moraleja; Ana López de Andrés; Rodrigo Jiménez-García
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  CREATE: A New Data Resource to Support Cardiac Precision Health.

Authors:  Seungwon Lee; Bing Li; Elliot A Martin; Adam G D'Souza; Jason Jiang; Chelsea Doktorchik; Danielle A Southern; Joon Lee; Natalie Wiebe; Hude Quan; Cathy A Eastwood
Journal:  CJC Open       Date:  2020-12-27

10.  Four-year incidence of diabetic retinopathy in a Spanish cohort: the MADIABETES study.

Authors:  Miguel Á Salinero-Fort; Francisco Javier San Andrés-Rebollo; Carmen de Burgos-Lunar; Francisco Jesús Arrieta-Blanco; Paloma Gómez-Campelo
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.